Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival
Authors:
- 18 April 2018
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 472 (5) , 739-748
Abstract
Well-differentiated pancreatic neuroendocrine neoplasms/tumors (PanNETs) are rare neoplasms with diverse clinical behavior. Biomarker discovery is important for predicting clinical course and prognosis of PanNET patients. Carbonic anhydrase 9 (CA9) and vimentin are hypoxia and epithelial-mesenchymal transition-related proteins of which expression in many carcinomas has been associated with poor prognosis, but their significance in PanNET has yet to be determined. We assessed CA9 and vimentin expression in 164 PanNETs and compared this with clinicopathologic characteristics. CA9 expression was observed in normal islets, while neuroendocrine microadenomas and small (< 1 cm) PanNETs showed loss of CA9 expression. CA9 and vimentin expression was observed in 38 (23%) and 36 (22%) of PanNETs, respectively. CA9 expression was associated with larger size (p = 0.001), higher grade (p < 0.001), higher pT category (p < 0.001), lymph node (p = 0.003) and distant (p = 0.047) metastases, higher AJCC stage (p < 0.001), and lymphovascular (p < 0.001) and perineural (p = 0.002) invasion. PanNET patients with CA9 expression had a shorter recurrence-free survival (5-year survival rate 47%) than those without CA9 expression (76%) by univariate (p = 0.001) but not multivariate analysis. Vimentin expression correlated with CA9 expression (p < 0.001) but not with other clinicopathologic factors. In conclusion, CA9 expression was observed in normal islets, while neuroendocrine microadenomas and small (< 1 cm) PanNETs showed CA9 expression loss. CA9 expression gradually reappeared in larger PanNETs, and this was associated with clinical progression and decreased patient survival by univariate but not multivariate analysis.Keywords
Funding Information
- Ministry of Education, Science and Technology (2016R1A2B4009381)
- Asan Institute for Life Sciences, Asan Medical Center (2013-554)
This publication has 49 references indexed in Scilit:
- The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated NeoplasmsAmerican Journal of Surgical Pathology, 2015
- Prognostic validation of the WHO 2010 grading system in pancreatic insulinoma patientsNeoplasma, 2015
- Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomasLung Cancer, 2013
- Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau PatientsClinical Cancer Research, 2012
- Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine TumorsAmerican Journal of Surgical Pathology, 2012
- Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine TumorsJournal of Clinical Oncology, 2011
- KIT is an Independent Prognostic Marker for Pancreatic Endocrine TumorsAmerican Journal of Surgical Pathology, 2009
- Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreasBritish Journal of Surgery, 2008
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-cateninExperimental Cell Research, 2003